These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36527566)

  • 1. PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study.
    Kocabaş U; Ergin I; Yavuz V; Murat S; Özdemir I; Genç Ö; Altın C; Tüner H; Meriç BK; Çoner A; Yüce Eİ; Boyraz B; Aslan O; Dal A; Şen T; İbişoğlu E; Erdoğan A; Özgeyik M; Demir M; Bilgel ZG; Şengör BG; Urgun ÖD; Doğduş M; Tekin DDN; Çakal S; Çayırlı S; Güler A; Karabulut D; Dalgıç O; Uzman O; Murat B; Şahin Ş; Karabulut U; Kıvrak T; Coşgun MS; Özyurtlu F; Kaplan M; Özçalık E;
    Cardiovasc Drugs Ther; 2024 Jun; 38(3):581-599. PubMed ID: 36527566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
    Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
    Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rates of Potentially Inappropriate Dosing of Direct-Acting Oral Anticoagulants and Associations With Geriatric Conditions Among Older Patients With Atrial Fibrillation: The SAGE-AF Study.
    Sanghai S; Wong C; Wang Z; Clive P; Tran W; Waring M; Goldberg R; Hayward R; Saczynski JS; McManus DD
    J Am Heart Assoc; 2020 Mar; 9(6):e014108. PubMed ID: 32146898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors Associated With the Choice of Oral Anticoagulant Class in the Older Patients: An Observational Study.
    Pagès A; Sabatier R; Sallerin B
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):332-337. PubMed ID: 32266832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Appropriateness of the Direct Oral Anticoagulants Dosing in the Middle East Gulf Region.
    Anouassi Z; Atallah B; Alsoud LO; El Nekidy W; Al Mahmeed W; AlJaabari M; Almuti K
    J Cardiovasc Pharmacol; 2021 Feb; 77(2):182-188. PubMed ID: 32925474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses.
    Briasoulis A; Gao Y; Inampudi C; Alvarez P; Asleh R; Chrischilles E; Leira EC; Vaughan-Sarrazin M
    BMC Cardiovasc Disord; 2020 Feb; 20(1):42. PubMed ID: 32013886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Anticoagulant Utilization Among United States Nursing Home Residents With Atrial Fibrillation From 2011 to 2016.
    Alcusky M; McManus DD; Hume AL; Fisher M; Tjia J; Lapane KL
    J Am Heart Assoc; 2019 May; 8(9):e012023. PubMed ID: 31046504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation.
    Chan YH; Chao TF; Chen SW; Lee HF; Yeh YH; Huang YC; Chang SH; Kuo CT; Lip GYH; Chen SA
    Heart Rhythm; 2020 Dec; 17(12):2102-2110. PubMed ID: 32702416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Creatinine clearance and inappropriate dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.
    Yagi N; Suzuki S; Arita T; Otsuka T; Semba H; Kano H; Matsuno S; Kato Y; Uejima T; Oikawa Y; Yajima J; Matsuhama M; Yamashita T
    Heart Vessels; 2020 Jan; 35(1):110-117. PubMed ID: 31222552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
    Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
    Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients.
    Dillinger JG; Aleil B; Cheggour S; Benhamou Y; Béjot Y; Marechaux S; Delluc A; Bertoletti L; Lellouche N
    Arch Cardiovasc Dis; 2018 Feb; 111(2):85-94. PubMed ID: 28988597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
    De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
    BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study.
    Liu T; Yang HL; Gu L; Hui J; Omorogieva O; Ren MX; Wang XH
    BMC Cardiovasc Disord; 2020 Jan; 20(1):22. PubMed ID: 31948390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Appropriateness of direct oral anticoagulant prescribing in older subjects with atrial fibrillation discharged from acute medical wards.
    De Vincentis A; Soraci L; Arena E; Sciacqua A; Armentaro G; Aucella F; Corsonello A; Aucella F; Antonelli Incalzi R
    Br J Clin Pharmacol; 2024 May; 90(5):1231-1239. PubMed ID: 38321367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates and Determinants for the Use of Anticoagulation Treatment before Stroke in Patients with Known Atrial Fibrillation.
    Giustozzi M; Agnelli G; Quattrocchi S; Acciarresi M; Alberti A; Caso V; Vedovati MC; Venti M; Paciaroni M
    Cerebrovasc Dis Extra; 2020; 10(2):44-49. PubMed ID: 32375143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Sood NA; Bunz TJ; Coleman CI
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
    Steinberg BA; Holmes DN; Piccini JP; Ansell J; Chang P; Fonarow GC; Gersh B; Mahaffey KW; Kowey PR; Ezekowitz MD; Singer DE; Thomas L; Peterson ED; Hylek EM;
    J Am Heart Assoc; 2013 Nov; 2(6):e000535. PubMed ID: 24275632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct Oral Anticoagulants and Non-valvular Atrial Fibrillation: Compliance with Dose Level Guidelines in Patients Aged 80 Years and Over.
    Cavillon Decaestecker M; Ferret L; Decaestecker K; Gautier S; Verdun S; Tsogli ES
    Drugs Aging; 2021 Oct; 38(10):939-950. PubMed ID: 34486094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF.
    Guenoun M; Cohen S; Villaceque M; Sharareh A; Schwartz J; Hoffman O; Dib JC; Ouazana L; Assouline S; Parrens E; Garban T; Pradeau V; Guedj-Meynier D; Lequeux B; Cohen C; Durand P; Dievart F; Dhanjal TS; Sabouret P; Lellouche N
    Europace; 2023 Oct; 25(10):. PubMed ID: 37801642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.